Imago BioSciences (NASDAQ:IMGO – Get Rating) is one of 942 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Imago BioSciences to similar companies based on the strength of its risk, institutional ownership, dividends, valuation, analyst recommendations, profitability and earnings.
This table compares Imago BioSciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Imago BioSciences Competitors||-3,136.96%||-1,455.34%||-9.04%|
This table compares Imago BioSciences and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Imago BioSciences||N/A||-$42.31 million||-1.30|
|Imago BioSciences Competitors||$1.86 billion||$250.59 million||-2.61|
Imago BioSciences’ peers have higher revenue and earnings than Imago BioSciences. Imago BioSciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
88.3% of Imago BioSciences shares are held by institutional investors. Comparatively, 45.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of Imago BioSciences shares are held by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current recommendations and price targets for Imago BioSciences and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Imago BioSciences Competitors||2588||12275||38407||606||2.69|
Imago BioSciences presently has a consensus price target of $34.75, suggesting a potential upside of 181.83%. As a group, “Pharmaceutical preparations” companies have a potential upside of 132.80%. Given Imago BioSciences’ stronger consensus rating and higher probable upside, analysts clearly believe Imago BioSciences is more favorable than its peers.
Imago BioSciences beats its peers on 7 of the 12 factors compared.
About Imago BioSciences (Get Rating)
Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.